Exclusive: UPSIDE Foods Submits $50m Stalking Horse Bid for Believer Meats’ US Cultivated Meat Facility

Why It Matters

Securing the Believer Meats facility would speed UPSIDE’s hybrid cell‑culture/plant‑based product rollout and consolidate its leadership as rivals struggle with financing. It also underscores a broader consolidation trend in the cultivated‑meat sector.

Key Takeaways

• UPSIDE Foods' $50M stalking horse bid sets baseline for asset sale.
• Facility includes 20,000‑L bioreactors and $150M of equipment.
• Sale excludes Israeli‑owned IP, raising future licensing questions.
• Competing offers must exceed $52.25M by July 20 deadline.
• Acquisition could accelerate UPSIDE’s hybrid meat strategy.

Pulse Analysis

The bankruptcy of Believer Meats has left a $150 million‑worth, state‑of‑the‑art cultivated‑meat plant idle in North Carolina. Court‑approved documents show the facility is equipped with large‑scale bioreactors, advanced automation, and FDA‑cleared processing lines, making it one of the few ready‑to‑scale sites in the United States. By submitting a $50 million stalking‑horse bid, UPSIDE Foods positions itself as the lead contender to acquire this infrastructure, while other bidders scramble to top the $52.25 million threshold before the July 20 deadline.

For UPSIDE, the purchase aligns with its pivot toward a hybrid protein model that blends cultured cell biomass with plant‑based ingredients. The company already holds U.S. regulatory clearance for its whole‑cut technology, but scaling that approach has proven costly and time‑intensive. Access to Believer’s 20,000‑liter reactors and associated process equipment could dramatically shorten the timeline to commercial production of hybrid products such as nuggets and patties, allowing UPSIDE to meet growing consumer demand without the capital outlay required to build a new plant from scratch.

Industry observers see the transaction as a bellwether for the cultivated‑meat market, where high‑capex projects and limited financing have forced several startups into distress. Consolidation around well‑funded players like UPSIDE may accelerate technology diffusion and bring cell‑based proteins closer to price parity with conventional meat. However, the exclusion of Israeli‑owned IP and unresolved licensing questions could create future legal complexities, underscoring the importance of clear intellectual‑property strategies as the sector matures.